Skip to main content

McKesson Ventures, LLC's Form 4 filing

Augmedix, Inc. (AUGX) · filed Sep 28, 2022

Accession no.
0001062993-22-019986
Filed
Sep 28, 2022
Trade date
Sep 26-27, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions. Open-market sales total $15.9K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
McKesson Ventures, LLCCIK 000182731210% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 26, 2022Common StockSSaleDisposed−2,300$1.56F1−$3,5884,022,340Direct
Sep 27, 2022Common StockSSaleDisposed−7,337$1.68F2−$12,326.164,015,003Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $1.48 to $1.64. The Reporting Persons undertake to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F2

The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $1.62 to $1.80. The Reporting Persons undertake to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)